ImmunoGen Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853

ImmunoGen, Inc. IMGN today announced that the Investigational New Drug (IND) application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, NSCLC, and other epithelial malignancies which over-express FOLR1. The Company expects Phase I evaluation of IMGN853 to begin in mid-2012. Recently the Company announced the start of Phase II testing with its IMGN901 compound in small-cell lung cancer and – earlier today – it announced the start of Phase I testing with its IMGN529 compound in non-Hodgkin's lymphoma. All three product candidates utilize the Company's Targeted Antibody Payload (TAP) technology with ImmunoGen antibodies and are wholly owned by the Company.